Aravive Investor Presentation Deck
GAS6 & AXL Expression Associated with Poor Survival in Many
Cancers
AXL expressed in >70%
of ovarian, pancreatic,
breast, kidney, and
uterine cancers
"Clinically, the expression
of GAS6 and TAM
receptors always predicts
poor prognosis"
Wu G, et al. Molecular insights of Gas6/TAM in
concer development and therapy; Cell Death and
Disease (2017) 8. e2700.
Tumor AXL Tumor
Type Expression
Ovarian
Pancreatic
Bladder
Uterine
Kidney
Breast
Lung
>70%
70%
>45%
>75%
> 70%
>75%
18-48%
Publications & Data
• Hao et al. 2017. AXL is highly expressed in ovary-derived tumors and is a prognostic gene in ovarian cancer.
• Rankin et al 2010. 73% of all ovarian tumor samples including both type I and type Il tumors were positive
for membranous AXL staining in the epithelium, demonstrating that AXL expression is significantly higher
(P<0.0001) in ovarian carcinomas than normal ovarian epithelium.
• Song et al. Cancer 2011. February 15;117(4):734-43. AXL is overexpressed in 70% stage II PDAC tumor
samples.
• Wang et al Transl Cancer Res 2019;8(3):976-984. High AXL expression was strongly correlated with low OS
(P<0.001).
#
Divine et al. Oncotarget. 2016 Nov 22; 7(47): 77291-77305: High immunohistochemical expression of AXL
was found in 76% of advanced-stage, and 77% of high-grade specimens and correlated with worse survival
in uterine serous cancer patients.
• Dalgin et al. 2007: AXL expression is 3-fold higher in tumor tissue than normal tissue.
• Gustafsson et al. 2009: AXL and GAS6 expression are implicated in RCC tumor advancement and severity
and negatively correlated to patient survival.
* Bottal et al. Breast Cancer. 2016. AXL expression correlates with the infiltration of CD163-positive cells in
tumor stroma and is associated with survival in triple negative breast cancer.
* Seike et al. Oncology Rep. 2017. 37: 3261-3269. The 5-yr survival rate for AXL+ or GAS6+ was significantly
lower than those for AXL-or GAS6- patients (51% vs. 75%; P-0.028 ; 53% vs. 72%; P=0.040)
* Linger et al. 2012. Expert Opin Ther Targets. 2010 October; 14(10): 1073-1090 AXL protein expression was
observed in 28 of 58 (48.3%) patient samples of lung adenocarcinoma
*The Cancer Genome Allas (TCGA), Axelrod and Pienta (AXL Review) Oncotarget 2014
Oct. 5/19) 8818-8852, Miao et al (AX. Review) 2017. Drug Target Review Article 22309
4View entire presentation